​

Halozyme Therapeutics (HALO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

HALO Stock Forecast

Halozyme Therapeutics (HALO) stock forecast, based on 26 Wall Street analysts, predicts a 12-month average price target of $79.67, with a high of $90.00 and a low of $70.00. This represents a 21.82% increase from the last price of $65.40.

$35 $46 $57 $68 $79 $90 High: $90 Avg: $79.67 Low: $70 Last Closed Price: $65.4

HALO Stock Rating

Halozyme Therapeutics stock's rating consensus is Buy, based on 26 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 16 Buy (61.54%), 9 Hold (34.62%), 1 Sell (3.85%), and 0 Strong Sell (0.00%).

Buy
Total 26 1 9 16 Strong Sell Sell Hold Buy Strong Buy

HALO Price Target Upside V Benchmarks

TypeNameUpside
StockHalozyme Therapeutics21.82%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts335
Avg Price Target$79.67$79.67$70.60
Last Closing Price$65.40$65.40$65.40
Upside/Downside21.82%21.82%7.95%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25233-19
Sep, 25233-19
Aug, 25234-110
Jul, 25233-19
Jun, 25223-18
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 20, 2025Morgan Stanley$79.00$67.0317.86%20.80%
Oct 14, 2025Leerink Partners$70.00$66.655.03%7.03%
Oct 02, 2025H.C. Wainwright$90.00$74.9420.10%37.61%
May 14, 2025Sean LaamanMorgan Stanley$62.00$66.58-6.88%-5.20%
Nov 15, 2024Joseph CatanzaroPiper Sandler$52.00$46.7211.30%-20.49%
Jun 07, 2024Mitchell KapoorH.C. Wainwright$65.00$51.4426.36%-0.61%
Jun 07, 2024Joseph CatanzaroPiper Sandler$51.00$51.44-0.86%-22.02%
Jun 07, 2024Mohit BansalWells Fargo$58.00$51.4412.75%-11.31%
Jun 06, 2024Corinne JenkinsGoldman Sachs$44.00$51.44-14.46%-32.72%
Jan 11, 2023Leerink Partners$61.00$55.709.52%-6.73%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 21, 2025H.C. WainwrightBuyBuyhold
Sep 24, 2025BenchmarkBuyBuyhold
Sep 22, 2025H.C. WainwrightBuyBuyhold
Aug 18, 2025Morgan StanleyOverweightOverweighthold
May 14, 2025Morgan StanleyOverweightOverweightdowngrade
Jan 10, 2025H.C. WainwrightBuyBuyhold
Nov 15, 2024Piper SandlerNeutralNeutralhold
Nov 04, 2024Piper SandlerNeutralNeutralhold
Nov 01, 2024Leerink PartnersMarket PerformMarket Performhold
Oct 18, 2024Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

$0 $2 $4 $6 $8 $10 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.95$2.86$1.48$2.13$3.50----
Avg Forecast$0.93$2.68$1.32$2.77$4.13$5.05$6.92$8.33$8.84
High Forecast$0.95$2.76$1.41$2.79$4.19$5.35$7.86$8.54$9.06
Low Forecast$0.90$2.62$1.28$2.74$4.08$4.72$6.24$7.90$8.63
Surprise %2.15%6.72%12.12%-23.10%-15.25%----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$267.59M$443.31M$660.12M$829.25M$1.02B----
Avg Forecast$265.21M$443.24M$671.79M$830.53M$1.00B$1.19B$1.47B$1.71B$1.83B
High Forecast$271.33M$453.46M$708.75M$838.20M$1.02B$1.21B$1.47B$1.72B$1.87B
Low Forecast$260.11M$434.71M$658.04M$827.36M$990.77M$1.18B$1.46B$1.71B$1.80B
Surprise %0.90%0.02%-1.74%-0.15%1.18%----

Net Income Forecast

$0 $300M $600M $900M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$129.09M$402.71M$202.13M$281.59M$444.09M----
Avg Forecast$129.76M$279.99M$331.72M$281.59M$554.68M$675.23M$946.10M$1.10B$1.19B
High Forecast$158.40M$335.99M$398.06M$337.91M$562.06M$717.60M$1.05B$1.15B$1.22B
Low Forecast$101.12M$224.00M$265.38M$225.28M$547.30M$632.86M$837.53M$1.06B$1.16B
Surprise %-0.52%43.83%-39.07%--19.94%----

HALO Forecast FAQ

Is Halozyme Therapeutics stock a buy?

Halozyme Therapeutics stock has a consensus rating of Buy, based on 26 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 16 Buy, 9 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Halozyme Therapeutics is a favorable investment for most analysts.

What is Halozyme Therapeutics's price target?

Halozyme Therapeutics's price target, set by 26 Wall Street analysts, averages $79.67 over the next 12 months. The price target range spans from $70 at the low end to $90 at the high end, suggesting a potential 21.82% change from the previous closing price of $65.4.

How does Halozyme Therapeutics stock forecast compare to its benchmarks?

Halozyme Therapeutics's stock forecast shows a 21.82% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Halozyme Therapeutics over the past three months?

  • October 2025: 22.22% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 11.11% Strong Sell.
  • September 2025: 22.22% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 11.11% Strong Sell.
  • August 2025: 20.00% Strong Buy, 30.00% Buy, 40.00% Hold, 0% Sell, 10.00% Strong Sell.

What is Halozyme Therapeutics’s EPS forecast?

Halozyme Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $5.05, marking a 44.29% increase from the reported $3.5 in 2024. Estimates for the following years are $6.92 in 2026, $8.33 in 2027, and $8.84 in 2028.

What is Halozyme Therapeutics’s revenue forecast?

Halozyme Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $1.19B, reflecting a 16.87% increase from the reported $1.02B in 2024. The forecast for 2026 is $1.47B, followed by $1.71B for 2027, and $1.83B for 2028.

What is Halozyme Therapeutics’s net income forecast?

Halozyme Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $675.23M, representing an 52.05% increase from the reported $444.09M in 2024. Projections indicate $946.1M in 2026, $1.1B in 2027, and $1.19B in 2028.